Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial

Gary E. Raskob(University of Oklahoma Health Sciences Center), Nick van Es(Amsterdam UMC Location University of Amsterdam), Annelise Segers, Pantep Angchaisuksiri(Ramathibodi Hospital), Doyeun Oh(CHA University), Z Boda(University of Debrecen), Roger M. Lyons(Texas Oncology), Karina Meijer(University Medical Center Groningen), Ivan Gudz(Ivano-Frankivsk National Medical University), Jeffrey I. Weitz(McMaster University), George Zhang(Daiichi Sankyo (United States)), Hans Lanz(Daiichi Sankyo (United States)), Michele Mercuri(Daiichi Sankyo (United States)), Harry R. Büller(Amsterdam UMC Location University of Amsterdam)
The Lancet Haematology
July 3, 2016
Cited by 155

Abstract


Related Papers

No related papers found

Powered by citation graph analysis